Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
adenocarcinoma/albumin
Veza se sprema u međuspremnik
Page 1 od 48 rezultati
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Primary outcome:
1. progression free survival (PFS) evaluated according to RECIST1.1.
Secondary outcome:
1. Objective Response Rate (ORR), Overall Survival (OS), Disease Control Rate (DCR), Duration of Response (DOR) evaluated according to RECIST1.1, and Quality of Life(QOL).
2. The overall
Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Patients who meet the inclusion criteria will receive Tislelizumab combined with Bevacizumab and albumin paclitaxel for 4 cycles. If there is no disease progression, the patient will continue to receive Tislelizumab maintenance therapy, until the disease progresses or death.
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of an immune checkpoint inhibitor in patients with advanced or recurrent gastric and esophagogastric junction adenocarcinoma, including two arms to compare the efficacy and safety of Albumin-bound Paclitaxel Plus
Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Pancreatic cancer has an extremely poor prognosis with a 5-year survival rate of less than 5%. About 25% of patients have the opportunity for radically surgical resection when diagnosis. However, the recurrence rate is up to 85% within 2 years. Data from clinical trials indicated that
Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Biliary tract cancer arises from the epithelial cells of the bile ducts. Until nowadays, no standard second-line treatment has been established following recurrence from the first-line treatment. Angiogenesis plays a key role in the carcinogenesis and development of biliary tract adenocarcinoma.
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
At present, the treatment mode of breast cancer has gradually turned to the individualized comprehensive treatment mode combining systemic therapy and local therapy, and neoadjuvant therapy is widely used. Albumin-bound paclitaxel alters the excipients, reduces adverse reactions and greatly enhances
Prospective Monocentric Clinical-biological Database
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Pancreatic adenocarcinoma (PA) is a solid cancer with a very poor prognosis with overall survival, all stages combined, not exceeding 5% at 5 years. The incidence and number of deaths caused by this type of tumor have been steadily increasing for two decades. In the absence of therapeutic advances,
Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Investigators hypothesize that malnutrition has an adverse impact on the clinical course of patients with advanced PDAC treated with chemotherapy.
Aims:
To investigate the association between the nutritional status and pancreatic exocrine function and the clinical outcomes of patients with advanced
Preoperative Endoscopic Treatment With Fosfomycin and Metronidazole in Patients With Right-sided Colon Cancer and Colon Adenoma (MEFO-trial)
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Background Dysbiosis and known bacterial drivers play a significant role in the carcinogenesis of colorectal cancer. Among bacterial drivers, Fusobacterium nucleatum (FN) and the formation of biofilm on the surface of the colonic epithelium are considered pro-carcinogenic. The increased permeability
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Title: Evaluation of the combined intraoperative monitoring of depth of analgesia (NOL), depth of anesthesia (BIS) and continuous hemodynamic data (Flotrac EV1000 system) on the patients' recovery after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). A pilot
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Pancreatic cancer continues to be a very lethal disease. It was estimated that in 2016, 53,070 Americans would be diagnosed with pancreatic ductal adenocarcinoma (PDA), and 41,780 would die from the disease. This makes pancreatic cancer the third leading cause of death from cancer in the US.
PDA is
A Study of Perioperative Oral Nutritional Support for Patients Having Surgery for Colon Cancer, Peri-Nutri
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
The hypothesis in this study are:
1. Perioperative ONS decreases surgery related morbidity
2. Perioperative ONS increases the quality of life after surgery
3. Perioperative ONS decreases the length of stay in institutional care
4. Perioperative ONS decreases 90-day mortality and improve 5-year
Association Between Helicobacter Pylori and Inflammatory Bowel Disease
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
PATIENT AND METHOD :
observation Cross sectional study will be conducted at assuit university hospitals on all patients with inflammatory disease to detect the prevalence of helicobacter pylori among them .Then the examined patients will be divided in to two group receiving the same medication group
Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Najkompletnija baza ljekovitog bilja potpomognuta naukom
- Radi na 55 jezika
- Biljni lijekovi potpomognuti naukom
- Prepoznavanje biljaka po slici
- Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
- Pročitajte naučne publikacije povezane sa vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima
